68 results about "Acute ischemic stroke" patented technology

The embodiment of the invention provides a cerebral apoplexy focus detection and scoring method and device based on a multi-modal medical image. The method comprises the following steps: acquiring medical images of various different modals of a suspected acute ischemic cerebral apoplexy patient; performing registration fusion and focus labeling on the medical images of different modalities based on an attention mechanism to obtain a labeled first modal image; training a target detection model of a YOLOv8 framework based on Swin-Transform improvement by using the labeled first modal image, and carrying out target detection on the to-be-detected image based on the trained target detection model to obtain an infarction region detection result; training a semantic segmentation model by using the labeled ASPECT scoring and partitioning brain atlas, performing scoring region segmentation on the to-be-detected image based on the trained semantic segmentation model, and outputting the ASPECT scoring and partitioning brain atlas; and mapping the infarct area detection result to the ASPECT score partition brain map, and calculating to obtain an ASPECT score.

The invention discloses a bionic nano system for treating acute ischemic stroke and application of the bionic nano system. According to the preparation method disclosed by the invention, the TNK-DNaseI (at) ZIF-8 nano-particles are prepared by loading the ZIF-8 with the TNK-DNaseI (at) ZIF-8 and then the TNK-DNaseI (at) ZIF-8 nano-particles are coated with the natural platelet membrane, so that the TNK-DNaseI (at) ZPM bionic nano-system is prepared. The bionic nano system can achieve efficient thrombolysis, obviously reduce the infarct area, improve neurological impairment and reduce bleeding complications. The invention provides a new drug choice for treating the acute ischemic stroke, and has a wide application prospect in the aspects of clinically treating the acute ischemic stroke and improving the prognosis of a patient with the acute ischemic stroke.

The invention relates to 4 serum peptide patterns for diagnostics of intracranial hemorrhagic stroke (ICH) in humans and differential diagnosis from acute ischemic stroke that are defined using a list of the 34 quantitative peptides that in sera of patients with ICH are increased 2 folds or more as compared with individuals without stroke and patients with acute ischemic stroke and a list of 16 qualitative peptides detectable in sera of the patients with ICH but not detectable in the sera of individuals without stroke and in sera of patients with acute ischemic stroke.

The invention belongs to the technical field of biological medicine. More specifically, the invention provides the annular RNACircMAP2, and the sequence of the annular RNACircMAP2 is as shown in SEQ ID NO. 1 or SEQ ID NO. 2. The invention proves that CircMAP2 can be used as a novel biomarker for diagnosing acute ischemic stroke for the first time. Compared with a traditional imaging diagnosis method, the acute ischemic stroke can be diagnosed by detecting the expression level of the CircMAP2 in the plasma and the plasma exosome of the patient, the cerebral infarction area of the acute ischemic stroke can be speculated through the expression level of the CircMAP2, and the method has the advantages of being easy and convenient to operate, high in detection speed and low in cost; the system is especially suitable for popularization and use in primary medical institutions. The product for diagnosing acute ischemic stroke provided by the invention can quickly and accurately diagnose acute ischemic stroke, and has good clinical popularization prospect and application value.

In MRI examinations of patients with acute ischemic stroke, it is often difficult for patients to fix and hold their heads due to impaired consciousness or limb weakness. Therefore, this invention provides a tool that is structurally rational, easy to operate, and effectively enhances the head fixation effect. [Solution] A tool to support MRI examination, comprising a base 1, a head rest member 2 with adjustable anterior-posterior position, a lateral limiting member 3 with an elastic buffer layer, and an adjustment mechanism 4. The head rest member slides relative to the base to adapt to the length of the patient's neck. The lateral limiting member is biased inward by a compression coil spring and flexibly holds both sides of the head with an elastic buffer layer, absorbing and suppressing involuntary movements. The adjustment mechanism uses a single reverse-threaded adjustment rod to synchronously and symmetrically move the left and right limiting plates, enabling precise adjustment according to the head circumference. This effectively limits multi-directional micro-movements of the head during imaging and improves image stability.

The present invention is directed to a method of treating acute ischemic stroke in a human comprising administering one of more low doses of DC009, wherein the dose is about 0.01-0.075 mg / kg / dose. The low dose administration is safe and effective in treating acute ischemic stroke in a human subject.

The invention belongs to the technical field of biology, and particularly relates to application of Lnc-PLBD1-AS1 and MCEMP1 as prognosis biomarkers of acute ischemic stroke. According to the application disclosed by the invention, it is found that the expression levels of baseline Lnc-PLBD1-AS1 and MCEMP1 of people who are dead within one year after an acute cerebral arterial thrombosis patient is attacked are obviously higher than those of survival patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of death of the acute cerebral arterial thrombosis patient within one year after the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient; the expression levels of the baselines Lnc-PLBD1-AS1 and MCEMP1 of people suffering from the adverse function outcome (death or severe disability) of acute cerebral arterial thrombosis patients after attack for 3 months are obviously higher than those of other patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of the adverse function outcome of the acute cerebral arterial thrombosis patients after attack for 3 months.

This invention relates to a pharmaceutical composition and its application for treating acute ischemic stroke. The pharmaceutical composition for treating acute ischemic stroke comprises separately packaged tissue-type plasminogen activator citPA5 and a platelet aggregation inhibitor. Its beneficial effects include significantly improving cerebral blood flow recovery, shortening thrombolysis time, reducing infarct volume, and improving neurological function without increasing the risk of bleeding, demonstrating a good synergistic thrombolytic effect.

Disclosed is a non-invasive system and related methods to deliver electrical current to ischemic brain tissue rapidly with minimal set up, to treat acute ischemic stroke via direct cytoprotection and by collateral blood flow enhancement promoting recanalization of occluded vessel. In one embodiment, the system includes a cap with plurality of electrodes which are operable in combination to deliver an electrical current when in contact onto skin of the head region of the subject. In one embodiment, the electrical current delivery is individualized to target each individual's ischemic tissue only. In one embodiment, the electrode positioning can be selected from pre-determined electrode montages according to the location of the ischemia and vessel occlusion site. In one embodiment, the system can be applied as a standalone treatment or adjunct to reperfusion therapies to salvage the at-risk ischemic tissue (aka penumbra) and improve patient outcomes.

In an automated detection system for acute ischemic stroke, a preprocessor performs registration on a whole-brain image and a standard-brain spatial template to extract individual brain region masks from the whole-brain image. A deep learning encoder performs feature extraction on the whole-brain image and the individual brain region masks, thereby converting the whole-brain image into 2D whole-brain slice images. A first processor maps the individual brain masks onto the whole-brain slice images for registration, thereby generating sets of brain region slice images. A second processor computes the stroke-related weight values of the slice images of each of the sets of brain region slice images and sums the weight values to obtain the characteristic value of each brain region. A disparity-aware classifier determines whether any brain region has acute ischemic stroke according to the characteristic value of each brain region.

Described are methods and systems for transcervical access of the cerebral arterial vasculature and treatment of cerebral occlusions, including ischemic stroke. The methods and devices may include methods and devices which may provide aspiration and passive flow reversal, those which protect the cerebral penumbra during the procedure to minimize injury to brain, as well as distal catheters and devices to remove an occlusion. The methods and devices that provide passive flow reversal may also offer to the user a degree of flow control. Devices and methods which provide a way to securely close the access site in the carotid artery to avoid the potentially devastating consequences of a transcervical hematoma are also described.

Disclosed in the present invention is a pharmaceutical composition, comprising anisodine or a salt thereof and 2-borneol or a related substance thereof. The pharmaceutical composition provided in the present invention exhibits synergistic effects in the treatment of cardiovascular and cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, and can effectively improve outcomes of patients with cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, thereby enhancing the quality of life of the patients.

The application belongs to the field of Zhuang and Yao medicine treatment of acute ischemic stroke, and discloses a Zhuang and Yao medicine compound medicine, a preparation method and application thereof in treating acute ischemic stroke. The Zhuang and Yao medicine compound medicine comprises the following raw materials in parts by weight: Ficus tikoua 55-62 parts, Camptotheca acuminata 12-17 parts, Ilex hainanensis 26-35 parts and Saposhnikovia divaricata 13-18 parts. The four raw materials are put into clean water, and the raw materials are prepared into a medicinal liquid to obtain the Zhuang and Yao medicine compound medicine. The Zhuang and Yao medicine compound medicine is cheap, convenient to use, has remarkable curative effect, can dredge the dragon road and the toxic evil and toxic side effects of the fire road, and has a simple preparation process.

The application discloses application of a 2-amino-pyrazine derivative in preparation of a medicine for treating and / or preventing apoplexy and complications, wherein the 2-amino-pyrazine derivative iMAP4K1 is (R)-4-[5-amino-6-[[1-(1-methyl-4-piperidyl)-4-pyrazolyl]oxy]-2-pyrazinyl]-N-[2-(3-fluoro-1-pyrrolidinyl)ethyl]-2,6-dimethylbenzamide; the apoplexy is acute ischemic stroke; and the 2-amino-pyrazine derivative can be used as an active ingredient in a medicine for treating and / or preventing post-stroke brain injury and complications, effectively reducing post-stroke cerebral infarction volume, improving sensory-motor and balance nerve functions, and preventing and treating post-stroke complications such as cerebral edema and acute lung injury.

The invention discloses a traditional Chinese medicine monomer nanoparticle oral delivery system based on intestinal liver circulation and a preparation method thereof, spherical nanoparticles (SA NPs) with the particle size of 194 + / -20 nm are formed through self-assembly of threat resin acid (SA), and the limitation of a traditional nano carrier is broken through: the oral bioavailability reaches 34.7% by utilizing an ASBT-mediated intestinal liver circulation mechanism; the gastric acid environment is tolerated (the pH is stable at 1.5), and after penetrating through the intestinal epithelium, the drug is targeted to ischemic brain tissues; the medicine has carrier-medicine dual functions, and the cerebral infarction volume is reduced by 34.1% when the medicine is singly used; after the neuroprotective peptide NA1 is loaded (the drug loading capacity is 5.8 wt%), the infarct volume is reduced by 68.7% through synergism. The system is suitable for pre-hospital first aid of cerebral apoplexy, and the freeze-dried powder can be stored at normal temperature for 12 months. The delivery system has a great application prospect in preparation of drugs for treating acute ischemic stroke needing rapid brain targeting.

The application discloses an acute ischemic stroke prognosis prediction method based on CTA images, relates to the technical field of medical image processing, and fuses a three-dimensional visual transformer and a meta-learning strategy to train a target prognosis prediction model based on the three-dimensional visual transformer and matched with a target data acquisition condition.The target prognosis prediction model can effectively model a spatial dependence relationship in a three-dimensional CTA image across regions and layers, significantly improves the recognition ability of complex cerebral vascular structures and ischemic regions compared with a traditional convolution network which only depends on a local receptive field, and further more, the introduction of the meta-learning strategy can improve the model generalization ability under small samples and multiple data acquisition conditions, so that the target prognosis prediction model directly takes the CTA image to be predicted as input to realize automatic prognosis prediction, does not need manual segmentation or feature extraction, avoids the dependence on manual experience in the traditional method, and improves the standardization degree and repeatability of the model application.

This application relates to the field of biomedical engineering, specifically disclosing a stem cell preparation for treating acute ischemic stroke and its preparation method. The preparation comprises a carrier core formed integrally through membrane fusion and an engineered stem cell membrane shell. The carrier core is a homologous stem cell exosome loaded with reactive oxygen species (ROS) scavenging nanoenzymes and can anchor responsive hydrogel microspheres encapsulating neurotrophic factors. The engineered shell covers the core, and its surface is covalently linked to brain-targeting molecules and thermosensitive lipid molecules, the latter of which can expose the target molecules at body temperature for intelligent navigation. The preparation method includes stepwise preparation of the drug-loaded core and functionalized shell, followed by programmed freeze-thaw treatment to induce membrane fusion of the two into a complete preparation. The product of this application can efficiently target ischemic lesions and achieve sequential synergistic treatment by first scavenging ROS and then releasing trophic factors. Its preparation method has advantages such as modularity, mild conditions, and good preservation of bioactivity.

The present application relates to the field of medicine, and discloses an integrated emergency stroke unit having regions. The integrated emergency stroke unit having regions comprises an information interaction area, an imaging examination area, and a thrombolysis treatment area. The information interaction area is provided with a doctor workstation, a comprehensive information monitoring display, and a process-support AI assistant. The imaging examination area is provided with a detection device, a first television display screen, a low-field movable magnetic resonance imager, and an AI-assisted decision-making system. The process-support AI assistant performs automated consultation and assists in nervous system scale scoring by means of voice interaction or touch screen input interaction, and also provides retrieval support for a real-time knowledge base and clinical guidelines. The AI-assisted decision-making system assists in decision-making on the basis of an automated consultation result, a scale scoring result, a detection result, and a head and neck magnetic resonance imaging result, generates a treatment plan, and displays the treatment plan. According to the present application, all diagnosis and treatment activities involved upon the arrival of a patient suffering from acute ischemic stroke at a hospital are integrated into a single space, which can significantly shorten diagnosis and treatment time.

The invention relates to systems and methods for predicting ischemic brain tissue fate from multi-phase CT-angiography. More specifically, systems and methods are provided that enable meaningful prediction of core, penumbra and perfusion from mCTA images using software that has been trained via machine learning to interpret mCTA images.

This invention relates to novel 2-(1-hydroxypentyl)benzoate, its preparation method, and its applications. Specifically, it relates to a cycloalkanamine 2-(1-hydroxypentyl)benzoate with the structure shown in Formula I, its preparation method, pharmaceutical compositions with the compound as the active ingredient, and the application of the compound in the treatment and / or prevention of ischemic cardiovascular and cerebrovascular diseases, especially mild, moderate, and severe acute ischemic stroke.

Described are methods and systems for transcervical access of the cerebral arterial vasculature and treatment of cerebral occlusions, including ischemic stroke. The methods and devices may include methods and devices which may provide aspiration and passive flow reversal, those which protect the cerebral penumbra during the procedure to minimize injury to brain, as well as distal catheters and devices to remove an occlusion. The methods and devices that provide passive flow reversal may also offer to the user a degree of flow control. Devices and methods which provide a way to securely close the access site in the carotid artery to avoid the potentially devastating consequences of a transcervical hematoma are also described.

The invention relates to the technical field of deep learning, and discloses an acute ischemic stroke function outcome prediction method and device based on deep learning. The method comprises the following steps: segmenting a preprocessed stroke lesion image sequence and a preprocessed deep marrow vein image sequence by using a deep learning image segmentation model; generating a first image sequence according to the preprocessed stroke lesion image sequence and the lesion segmentation mask sequence; generating a second image sequence according to the preprocessed deep marrow vein image sequence and the deep marrow vein segmentation mask sequence; processing the first image sequence and the second image sequence by using a deep learning classification model to obtain a first functional result prediction result and a second functional result prediction result; and generating a stroke functional result prediction result based on the first functional result prediction result and the second functional result prediction result. According to the invention, the stroke function outcome can be predicted more quickly and accurately.

The invention relates to a polypeptide of SEQ ID NO: 1 for use in the treatment of acute ischaemic stroke (AIS) or in the prevention of the complications of AIS in an adult mammalian subject. The polypeptide can be used in patients in whom AIS is followed by reperfusion of ischemic brain tissue, or in patients in whom AIS is not followed by reperfusion of ischemic brain tissue (patients with permanent cerebral ischemia).

The invention discloses a composition for treating acute ischemic stroke and a preparation method of the composition. The composition is prepared from 80 mg / ml-2. 20 mg / ml of edaravone, 0.48 mg / ml-0. 52 mg / ml of dextroborneol, 0.06 ml / ml-0. 10 ml / ml of propylene glycol, 0.80 mg / ml-1. 20 mg / ml of sodium pyrosulfite and the balance of water for injection, and the pH value of the composition is 3.5-5.5. According to the present invention, the liquid preparation process is optimized and improved, and the step-by-step preparation and mixing process of dissolving edaravone by using 35-45% of the prescription amount of propylene glycol (heating) and dissolving dextroborneol by using the remaining prescription amount of propylene glycol (room temperature) is adopted, such that the drug dissolving effect is ensured, the liquid preparation time can be substantially shortened, the liquid preparation efficiency can be substantially improved, and the industrial production benefit can be well met.

This invention discloses a method for determining collateral circulation indicators based on single-phase CTA, including acquiring single-phase CTA images and DWI images; preprocessing the images to obtain first images at different levels; registering and identifying the blood-supplying brain tissue regions in the first images at different levels to obtain second images at different levels; identifying the ischemic foci area as the vascular aggregation area based on the DWI images, and mapping the vascular aggregation area to the second images at different levels to obtain third images at different levels; calculating the ratio of the area of ​​the vascular aggregation circle to the area of ​​the healthy side vascular circle in the third images at different levels; calculating the mean value based on the ratio and the number of third images, and determining it as the collateral circulation indicator value of the single-phase CTA image to obtain an intuitive and accurate assessment result. This method can be applied to the field of collateral circulation assessment in acute ischemic stroke based on single-phase CTA.

The present disclosure relates to dosage regimens for the administration of a recombinant apyrase protein and their medical use in the treatment of ischemic events in a patient, such as ST-segment elevation myocardial infarction and acute ischemic stroke.